To keep the transplantation community informed about recently published level 1 evidence in organ transplantation ESOT and the Centre for Evidence in Transplantation have developed the Transplant Trial Watch.
The Transplant Trial Watch is a monthly overview of 10 new randomised controlled trials (RCTs) and systematic reviews. It includes a brief description of each study, an assessment of the reporting of some methodological quality features and the main conclusions of the report written by the Centre for Evidence in Transplantation (CET). RCTs and systematic reviews are selected by the Centre for Evidence in Transplantation on the basis of quality or interest. Electronic publications ahead of print are listed as [record in progress].
The first issue of the Transplant Trial Watch was published in September 2009. It is now made available to thousands of transplant professionals worldwide each month.
Click on each trial for more detail of findings and quality.
Risk factors for BK virus viremia and nephropathy after kidney transplantation: A systematic review.
Demey B, Tinez C, et al. J Clin Virol. 2018; 109:6-12.
A Randomized Clinical Trial Comparing Nitrofurazone-coated and Uncoated Urinary Catheters in Kidney Transplant Recipients: Results from a Pilot Study.
Menezes FG, Corrêa L, et al. Transpl Infect Dis. 2018; [record in progress].
Less renal allograft fibrosis with valganciclovir prophylaxis for cytomegalovirus compared to high-dose valacyclovir: a parallel group, open-label, randomized controlled trial.
Reischig T, Kacer M, et al. BMC Infect Dis. 2018; 18(1):573.
Early conversion of pediatric kidney transplant patients to everolimus with reduced tacrolimus and steroid elimination: Results of a randomized trial.
Tonshoff B, Ettenger R, et al. Am J Transplant. 2018; [record in progress].
Albuminuria and Allograft Failure, Cardiovascular Disease Events, and All-Cause Death in Stable Kidney Transplant Recipients: A Cohort Analysis of the FAVORIT Trial.
Weiner DE, Park M, et al. Am J Kidney Dis. 2018; [record in progress].
Somatostatin as Inflow Modulator in Liver-transplant Recipients With Severe Portal Hypertension: A Randomized Trial.
Troisi RI, Vanlander A, et al. Ann Surg. 2018; [record in progress].
Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Heart Transplant Recipients.
Arora S, Andreassen AK, et al. Circ Heart Fail. 2018; 11(9):e004050.
A Randomized Controlled Trial of Naloxone for Optimization of Hypoxemia in Lung Donors after Brain Death.
Dhar R, Stahlschmidt E, et al. Transplantation, 2018; [record in progress].
A Randomized Study of Quantiferon-CMV-Directed Versus Fixed Duration Valganciclovir Prophylaxis to Reduce Late CMV Following Lung Transplantation.
Westall GP, Cristiano Y, et al. Transplantation, 2018; [record in progress].
Donor-specific Cell-Free DNA as a Biomarker in Solid Organ Transplantation. A Systematic Review.
Knight SR, Thorne A, Faro MLL. Transplantation, 2018; [record in progress].